Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharmather Hldgs Ltd (PHRM.CN)

Pharmather Hldgs Ltd (PHRM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 21,601
  • Shares Outstanding, K 88,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,416 K
  • 60-Month Beta 3.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.11
Trade PHRM.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2000 +20.00%
on 04/10/24
0.3900 -38.46%
on 03/28/24
-0.0900 (-27.27%)
since 03/26/24
3-Month
0.1700 +41.18%
on 03/05/24
0.4300 -44.19%
on 03/19/24
-0.0150 (-5.88%)
since 01/26/24
52-Week
0.0800 +200.00%
on 06/19/23
0.4300 -44.19%
on 03/19/24
+0.1200 (+100.00%)
since 04/26/23

Most Recent Stories

More News
Stocks in play: PharmaTher Inc

Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing ...

PHRM.CN : 0.2400 (-2.04%)
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1800 (unch)
PHRM.CN : 0.2400 (-2.04%)
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and...

PHRM.CN : 0.2400 (-2.04%)
PHRRF : 0.1800 (unch)
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.2400 (-2.04%)
PHRRF : 0.1800 (unch)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.2400 (-2.04%)
PHRRF : 0.1800 (unch)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1800 (unch)
PHRM.CN : 0.2400 (-2.04%)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.2400 (-2.04%)
PHRRF : 0.1800 (unch)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1800 (unch)
PHRM.CN : 0.2400 (-2.04%)
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Third FDA orphan drug designation for ketamine granted to PharmaTher...

PHRRF : 0.1800 (unch)
PHRM.CN : 0.2400 (-2.04%)
Stocks in play: PharmaTher Inc

Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The ...

PHRM.CN : 0.2400 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

See More

Key Turning Points

3rd Resistance Point 0.2983
2nd Resistance Point 0.2767
1st Resistance Point 0.2583
Last Price 0.2400
1st Support Level 0.2183
2nd Support Level 0.1967
3rd Support Level 0.1783

See More

52-Week High 0.4300
Fibonacci 61.8% 0.2963
Fibonacci 50% 0.2550
Last Price 0.2400
Fibonacci 38.2% 0.2137
52-Week Low 0.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar